Stock GLAND GLAND PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gland Pharma Limited Bombay S.E.

Equities

GLAND

INE068V01023

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:53 2024-07-12 am EDT 		5-day change 1st Jan Change
2,029 INR -1.07% Intraday chart for Gland Pharma Limited +10.19% +5.48%
Jun. 20 Fosun Pharma Trims Stake in Gland Pharma to 51.83% MT
Jun. 18 Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million CI

Valuation

Fiscal Period: March 2021 2022 2023 2024 2025 2026
Capitalization 1 405,432 537,705 208,882 334,726 - -
Enterprise Value (EV) 1 375,414 506,809 171,208 288,736 311,592 305,100
P/E ratio 39.3 x 44.4 x 26.7 x 39.4 x 31.7 x 27.2 x
Yield - - - 1.08% 0.21% 0.11%
Capitalization / Revenue 11.7 x 12.2 x 5.76 x 5.37 x 5.32 x 4.69 x
EV / Revenue 10.8 x 11.5 x 4.72 x 5.1 x 4.96 x 4.27 x
EV / EBITDA 28.8 x 33.6 x 16.7 x 21.7 x 19.4 x 16.3 x
EV / FCF 99.8 x 181 x 120 x 47.6 x -175 x 46.5 x
FCF Yield 1% 0.55% 0.84% 2.1% -0.57% 2.15%
Price to Book 6.51 x 7.48 x 2.62 x 3.48 x 3.41 x 3.14 x
Nbr of stocks (in thousands) 163,593 164,303 164,701 164,752 - -
Reference price 2 2,478 3,273 1,268 2,032 2,032 2,032
Announcement Date 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net sales 1 26,332 34,629 44,007 36,246 56,647 62,870 71,439
EBITDA 1 - 13,022 15,102 10,248 13,331 16,103 18,735
EBIT 1 - 12,034 13,999 8,780 9,885 12,914 14,876
Operating Margin - 34.75% 31.81% 24.22% 17.45% 20.54% 20.82%
Earnings before Tax (EBT) 1 - 13,348 16,186 10,546 11,325 14,771 16,132
Net income 1 - 9,970 12,117 7,810 7,725 10,554 12,409
Net margin - 28.79% 27.53% 21.55% 13.64% 16.79% 17.37%
EPS 2 - 62.99 73.64 47.43 46.89 64.18 74.82
Free Cash Flow 1 - 3,762 2,800 1,430 6,069 -1,776 6,564
FCF margin - 10.86% 6.36% 3.95% 10.71% -2.82% 9.19%
FCF Conversion (EBITDA) - 28.89% 18.54% 13.96% 45.52% - 35.04%
FCF Conversion (Net income) - 37.73% 23.11% 18.31% 78.56% - 52.9%
Dividend per Share 2 - - - - 20.00 4.250 2.333
Announcement Date 7/10/20 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 8,877 11,539 10,805 10,633 11,030 8,569 10,444 9,383 7,850 12,087 13,439 14,508 15,710 14,733
EBITDA 1 3,277 4,363 3,766 3,489 3,484 2,699 2,969 2,896 1,684 2,982 3,128 3,600 3,708 3,443
EBIT 1 3,028 4,110 3,505 3,211 3,173 2,350 2,602 2,520 1,309 2,286 2,299 2,769 2,734 2,640
Operating Margin 34.1% 35.62% 32.44% 30.2% 28.77% 27.43% 24.91% 26.85% 16.67% 18.92% 17.11% 19.09% 17.4% 17.92%
Earnings before Tax (EBT) 1 3,489 4,718 4,007 3,656 3,805 3,085 3,241 3,108 1,112 2,613 2,828 3,354 3,302 3,053
Net income 1 2,604 3,507 3,021 2,730 2,859 2,292 2,412 2,319 786.8 1,941 2,161 2,332 2,336 2,061
Net margin 29.33% 30.39% 27.96% 25.68% 25.92% 26.74% 23.1% 24.72% 10.02% 16.06% 16.08% 16.07% 14.87% 13.99%
EPS 2 - 21.37 18.37 16.62 17.36 13.92 14.65 14.08 4.780 11.78 12.70 13.60 14.23 13.30
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 5/17/21 7/21/21 10/22/21 1/21/22 5/19/22 7/20/22 10/26/22 1/23/23 5/18/23 8/7/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 30,018 30,896 37,674 15,197 23,134 29,626
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - 3,762 2,800 1,430 6,069 -1,776 6,564
ROE (net income / shareholders' equity) - 20.9% 18.6% 10.3% 9.26% 11% 11.4%
ROA (Net income/ Total Assets) - 18.8% 16.9% 9.4% 7.95% 9.84% 10.2%
Assets 1 - 52,911 71,651 83,056 97,194 107,250 121,656
Book Value Per Share 2 - 381.0 438.0 483.0 530.0 595.0 648.0
Cash Flow per Share 2 - - - 22.10 60.50 61.80 -
Capex 1 - 2,288 5,113 2,209 3,899 4,668 3,286
Capex / Sales - 6.61% 11.62% 6.1% 6.88% 7.42% 4.6%
Announcement Date 7/10/20 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gland Pharma Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
2,032 INR
Average target price
1,859 INR
Spread / Average Target
-8.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GLAND Stock
  4. GLAND Stock
  5. Financials Gland Pharma Limited